We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Exeltis

News List

Alvogen Inks Agreement with Exeltis contractpharma
June 20, 2019
Acquires a targeted portfolio of 23 prescription and OTC drugs in the field of women’s healthcare.
Exeltis USA, Inc. Announces the Approval of Slynd (drospirenone), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window drugs
June 11, 2019
Exeltis USA, Inc. Announces the Approval of Slynd (drospirenone), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window.
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Slinda (drospirenone) Developed by Exeltis drugs
December 03, 2018
The pharmaceutical multinational Exeltis, with a strong position in Women's Health, has received acceptance from the US Food and Drug Administration (FDA) of the filing.....